Tatsu Shimoyama - Concepedia

Author

Tatsu Shimoyama

Tokyo Metropolitan Komagome Hospital

Also Known As

Hiroshi Yabusaki, T Shimoyama, T. Shimoyama, Tatsu Shimoyama

144

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Tokyo Metropolitan Komagome Hospital National Cancer Center Hospital East Tokyo National Hospital National Cancer Center Nagoya Medical Center

About

Tatsu Shimoyama is an author at Tokyo Metropolitan Komagome Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	20	1.7K
2	Health Sciences	6	6	906
3	Engineering	3	3	227
4	Public Health	2	2	89
5	Biomedical Engineering	1	1	23

Tatsu Shimoyama

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial Sun Young Rha, Do‐Youn Oh, Patricio Yañez, The Lancet Oncology Chemotherapy Versus PlaceboGastrointestinal OncologyMedicineClinical TrialsImmune Checkpoint Inhibitor	2023	521
Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor Hideharu Kimura, Kazuko Sakai, Tokuzo Arao, Cancer Science	2007	276
Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients Sarah Park, Chikako Shimizu, Tatsu Shimoyama, Breast Cancer Research and Treatment Systems BiologyOncologyEngineeringBreast OncologyAtp-binding Cassette	2006	179
Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells Y Basaki, Fumihito Hosoi, Yoshinao Oda, Oncogene Y-box-binding Protein 1MedicineAkt-dependent Nuclear LocalizationMalignant CharacteristicsRadiation Oncology	2006	166
Establishment of a human non‐small cell lung cancer cell line resistant to gefitinib Fumiaki Koizumi, Tatsu Shimoyama, Fumiko Taguchi, International Journal of Cancer	2005	158
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study Tadeusz Robak, Jie Jin, Halyna Pylypenko, The Lancet Oncology Hematological MalignancyFrontline BortezomibLymphoid NeoplasiaTransplantationOncology	2018	132
A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors Tomohide Tamura, Hironobu Minami, Yasuhide Yamada, Journal of Thoracic Oncology Dose-escalation StudyMedicineMalignant TumorsCancer TreatmentClinical Radiation Oncology	2006	130
Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial Kensei Yamaguchi, Yung‐Jue Bang, Satoru Iwasa, Journal of Clinical Oncology	2022	105
Randomized Pharmacokinetic and Pharmacodynamic Study of Docetaxel: Dosing Based on Body-Surface Area Compared With Individualized Dosing Based on Cytochrome P450 Activity Estimated Using a Urinary Metabolite of Exogenous Cortisol Noboru Yamamoto, Tomohide Tamura, Haruyasu Murakami, Journal of Clinical Oncology	2005	86
Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors Noboru Yamamoto, Atsushi Horiike, Yasuhito Fujisaka, Cancer Chemotherapy and Pharmacology OncologySolid TumorsMedicinePharmacokinetic StudyCancer Growth	2007	80

Page 1